with autologous CAR-Ts, like Keytruda, they have to use the patients own blood to make the drug, but with allogeneic Azercell, it can be made from any blood, meaning it’s an off the shelf treatment that can be mass manufactured, as opposed to a bespoke, one-off individual treatment with autologous therapy. I hope you’re getting this now.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $80.77M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 27.0¢ | $461.4K | 1.681M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 134437 | 7 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |